- Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for millions of patients worldwide.
- Access to accurate and reliable diagnostic tests help clinicians improve patient care, limit healthcare spending and contribute to protecting public health.
- The cobas 5800 System is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes so clinicians can quickly determine the best treatment strategies for their patients.
“Diagnostics continue to revolutionise how providers care for patients, and it is essential, now more than ever, that the healthcare community has access to reliable and accurate testing solutions,” said Thomas Schinecker, CEO
The cobas 5800 system, the newest member of the Roche Molecular Work Area, is built upon the innovation of the cobas® 6800 and cobas® 8800 systems, making molecular testing accessible to more patients around the world.
About the cobas 5800 System
The cobas 5800 System is a real-time PCR molecular testing solution that provides excellent performance and value-added utility from a compact footprint. The cobas 5800 System delivers automation, consolidation, integration and standardisation – making it a scalable, cost-efficient solution for smaller labs seeking big lab performance, or for bigger labs seeking small lab agility.
The system is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation and delivery to the laboratory information system (LIS). The single module enables a walkaway time of up to eight hours*, resulting in less hands-on time, which can lead to improved productivity, reduced possibility for errors and more predictable turnaround times.
The cobas 5800 System will offer the same menu as the cobas 6800 and 8800 Systems, including the cobas® SARS-CoV-2 test. The system offers an expanded on board capacity allowing labs to test multiple assays simultaneously and delivers up to 144 results in an eight-hour shift. This streamlined molecular testing system will allow most labs to consolidate greater than 90 percent** of their routine molecular tests onto a single platform. For more information please visit diagnostics.roche.com.
About
Founded in 1896,
The
All trademarks used or mentioned in this release are protected by law.
*Walkaway time is dependent on the number of tests performed and number of runs initiated (under continuous testing conditions >96 tests per shift, walkaway time may be between 4 - 8 hours).
**May vary based on assay availability in your country.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Dr. Phone: +41 61 687 05 17 | Sileia Urech Phone: +41 79 935 81 48 |
Dr. Phone: +41 61 687 89 67 | Phone: +41 61 682 28 31 |
Nina Mählitz Phone: +41 79 327 54 74 | Phone: +41 61 687 43 05 |
Roche Investor Relations
Dr. Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com | Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
Dr. Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com | Dr. Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | Dr. Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Investor Relations | |
Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Attachment
- 18112021_MR_cobas 5800
© OMX, source